A Real-World study assessing the impact of neutralizing monoclonal antibody NmAb treatment in patients with an established diagnosis of COVID-19 infections
Latest Information Update: 06 Jul 2021
At a glance
- Drugs Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 06 Jul 2021 New trial record
- 24 Jun 2021 Results published in the Clinical Infectious Diseases